Breaking News

Financial Report: AMRI 


May 6, 2014

Decline in royalties impacts results

AMRI 

 
1Q Revenues: $59.3 million (flat)

1Q Earnings: $3.5 million (-46%)

Comments: Contract revenue was $51.0 million in the quarter, up 10%. Royalties were $8.3 million, down 36% due to generic competition for Allegra in Japan. Discovery Services and Development / Small Scale Manufacturing (DDS) contract revenue for the first quarter was $19.5 million, a decrease of 3%. Decreases in Discovery revenues were partially offset by increases in Development/Small Scale Manufacturing. Large Scale Manufacturing contract revenue was $31.5 million, up 19%.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision